An age-old question.

June 1, 2017. A pooled analysis in JCO of patient data from 16 trials of concurrent chemoradiation for stage III NSCLC reports that, despite having similar PFS, older (>70) patients had worse survival, more toxicity, and more grade 5 toxicity with chemoradiation than younger patients. It's no big surprise our assessment of patient fitness for current lung cancer treatment regimens could use some work. Sounds like advanced NSCLC could use a trial like this one in GBM randomizing older patients to aggressive versus conservative treatment.


Popular Posts